CIK 0001404281
- Non-accelerated filer
- Smaller reporting company
Eledon Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 949-238-8090
- Business address
- 19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
- Former names
- Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-15 | Harrison Seth Loring Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2015-06-17 | Harrison Seth Loring Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion | +7,549,570 | 7,549,579 | ||
| 2014-09-22 | Harrison Seth Loring Director | Purchase | +362,500 | $15.00 | $5.4M | 7,912,079 |
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series A Preferred Stock | −4,500,000 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series B-1 Preferred Stock | −798,067 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series B-2 Preferred Stock | −644,786 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series C Preferred Stock | −14,604,833 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series D-1 Preferred Stock | −8,711,335 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series D-2 Preferred Stock | −1,539,643 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series D-3 Preferred Stock | −24,046,035 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series E Preferred Stock | −24,199,308 | 0 |
Page 1 of 1 · 12 trades